Study in vitro of the anticancer activity of [3-allyl-4-(41-methoxyphenyl)-3H-thiazole-2-ylidene]-(32-trifluoromethylphenyl)amine hydrobromide toward human tumor cells

Abstract

In vitro study and characterization of [the] anticancer activity of heterocyclic derivative -[3-allyl-4-(4 1 -methoxyphenyl)-3H-thiazole-2-ylidene]-(3 2 -trifluoromethylphenyl)amine hydrobromide. Methods. The cell culture; MTT assay. Results. We synthesized [3-allyl-4-(4 1methoxyphenyl)-3H-thiazole-2-ylidene]-(3 2 -trifluoromethylphenyl)amine hydrobromide, which possessed the cardioprotective, as well as the hypolipidemic, anti-inflammatory, analgesic, antihypertensive and antioxidant effects. Here, we investigated its growth inhibitory action towards tumor cell lines of various tissue origin[s]: leukemia (HL-60, Jurkat), liver (HepG2), breast (MCF-7), lung (A549), cervical (KB3-1) and glioma (U251, U373, T98G) cells. We found that the leukemia cells were the most sensitive to the action of [3-allyl-4-(4 1methoxyphenyl)-3H-thiazole-2-ylidene]-(3 2 -trifluoromethylphenyl)amine hydrobromide with a mean of IC 50 values at 7.5-8.9 μg/mL. Conclusions. The anti-proliferative activity of [3-allyl-4-(4 1 -methoxyphenyl)-3H-thiazole-2-ylidene]-(3 2 -trifluoromethylphenyl)amine hydrobromide dropped in the order: leukemia > hepatocarcinoma ~ cervix > lung carcinoma > glioblastoma > breast carcinoma cells. Thus, we revealed in one molecule of ([3-allyl-4-(4 1methoxyphenyl)-3H-thiazole-2-ylidene]-(3 2 -trifluoromethylphenyl)amine hydrobromide) a combination of both the cardioprotective and anticancer activities that is of great significance for this agent as a potent anticancer medicine. K e y w o r d s: [3-allyl-4-(4 1 -methoxyphenyl)-3H-thiazole-2-ylidene]-(3 2 -trifluoromethylphenyl)amine hydrobromide, cytotoxicity in vitro, anticancer activity.